IASLC 2022 World Conference on Lung Cancer
Industry Sponsored Symposium

The Expanding Toolbox: Key Updates for ADCs in Lung Cancer

Monday, 8 August 2022 | 13:30-14:30 CET
Strauss 3, Messe Wien Exhibition & Congress Center
Wien, Austria

Objectives

- Review arising molecular markers in lung cancer
- Introduce ADC technology and its potential use in lung cancer
- Review current data for ADCs in NSCLC/SCLC and discuss how ADCs may be integrated into the NSCLC/SCLC treatment landscape

Faculty

Michael Thomas, MD
Thoraxklinik Heidelberg
gGmbH Universitätsklinikum
Heidelberg
Heidelberg, Germany

Tony Mok, MD
The Chinese University of
Hong Kong
Hong Kong

Charles Rudin, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Agenda

13:30-13:35 Introduction
Michael Thomas, MD

Michael Thomas, MD

13:55-14:15 Key Data Releases for ADCs in NSCLC
Tony Mok, MD

14:15-14:25 Implications of Current ADC Data for SCLC
Charles Rudin, MD, PhD

14:25-14:30 Q&A Session
Faculty Panel

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

This symposium is intended for HCPs in attendance and may discuss agents and products in development. This Industry Satellite Symposium is organized and funded by Daiichi Sankyo.

This Industry Satellite Symposium is not available to delegates from Japan.

©2022 Daiichi Sankyo Europe GmbH. GLM-GCS-MONC-0161 06/22